2021
DOI: 10.3390/jcm10194378
|View full text |Cite
|
Sign up to set email alerts
|

Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease

Abstract: The administration of beta-blockers is challenging and their efficacy is unclear in heart failure (HF) patients with chronic obstructive pulmonary disease (COPD). This study aimed to investigate the association of beta-blockers with mortality in such patients. This multicenter observational cohort study included hospitalized HF patients with a left ventricular ejection fraction <50% and evaluated them retrospectively. COPD was diagnosed based on medical records and/or the clinical judgment of each investiga… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 41 publications
0
2
0
Order By: Relevance
“…The BLOCK-COPD trial showed hospitalization for exacerbation was more common in metoprolol than placebo group in patient with moderate or severe COPD [30]. Higuchi et al reported the use of beta-blockers were associated with lower all-cause mortality due to lower non-cardiac mortality in patients with HF and COPD [31]. Overall, the benefit of beta-blockers seems to overweigh the potential harm.…”
Section: Discussionmentioning
confidence: 99%
“…The BLOCK-COPD trial showed hospitalization for exacerbation was more common in metoprolol than placebo group in patient with moderate or severe COPD [30]. Higuchi et al reported the use of beta-blockers were associated with lower all-cause mortality due to lower non-cardiac mortality in patients with HF and COPD [31]. Overall, the benefit of beta-blockers seems to overweigh the potential harm.…”
Section: Discussionmentioning
confidence: 99%
“…Clinical trials and large meta-analyses have shown that cardioselective beta-blockers are safe and are associated with a better prognosis in patients with stable COPD and concurrent CAD, particularly those with milder COPD, even though some results may have been affected by the bias inherent in observational studies. [51][52][53][54][55][56][57][58] In contrast, a recent randomized controlled trial (BLOCK-COPD) found no effect of metoprolol in reducing the incidence of exacerbations among patients with moderate to severe COPD who did not have an established indication for the beta-blocker treatment. 59 In summary, in the present study, we showed that COPD was undiagnostic in cardiac patients, especially in individuals with stable and mildly symptomatic disease.…”
mentioning
confidence: 99%